|
IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC). |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche |
|
|
Travel, Accommodations, Expenses - Novartis; Pfizer |
|
|
Honoraria - Amgen; Celgene; Daiichi Sankyo; Novartis; Roche |
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche/Genentech |
Research Funding - Novartis (Inst); Roche (Inst) |
|
|
|
Honoraria - AstraZeneca; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); Roche (Inst) |
|
|
Honoraria - Amgen; Novartis; Roche |
Consulting or Advisory Role - Amgen; Novartis; Roche |
|
|
Honoraria - Novartis; Roche |
Consulting or Advisory Role - Genentech/Roche; Inivata; Lilly; Pieris Pharmaceuticals |
Research Funding - Genentech (Inst); Lilly (Inst); Merrimack; Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Caris Centers of Excellence; Genentech/Roche; Inivata |
Other Relationship - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
Stock and Other Ownership Interests - MedSIR |
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Merus; Roche |